title: Verapamil reverses cardiac iron overload in streptozocin-induced diabetic rats.
abstract: Accumulating evidence shows that iron overload is a new risk factor for diabetes mellitus. L-type Ca(2+) channel (LTCC) has been identified as an important mediator for ferrous iron uptake into cardiomyocytes. In this study, we aimed to examine the effects of verapamil, the LTCC blocker, on myocardial iron metabolism in diabetic rats. Diabetes was induced by intraperitoneal injection of streptozocin after intragastric administration of fat emulsion, and then treated by verapamil (5 mg · kg(-1) · day(-1)) for 1 week. The results showed that verapamil did not alter the blood glucose level of diabetic rats. However, elevated levels of superoxide dismutase, malonaldehyde, and serum ferritin in diabetic rats were decreased significantly by verapamil treatment. Moreover, serum, myocardial, and urine iron were elevated remarkably along with a decrease of hepatic iron in diabetic rats. After verapamil administration, serum and myocardial iron in diabetic rats were reduced significantly but urine and hepatic iron were increased. Furthermore, confocal microscopy demonstrated that intracellular-free iron concentration was elevated dramatically in cardiomyocytes of diabetic rats, which was markedly attenuated after verapamil treatment. In summary, our data demonstrated that verapamil prevented myocardial iron overload by inhibiting intracellular iron accumulation in diabetic cardiomyocytes.
authors.affiliation: Key Laboratory of Drug Research, Heilongjiang Higher Education Institutions, Harbin Medical University, Harbin, People's Republic of China.
authors.forename: Hong-li
authors.initials: HL
authors.lastname: Shan
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Jian-wei
authors.initials: JW
authors.lastname: Wu
authors.forename: Peng-zhou
authors.initials: PZ
authors.lastname: Hang
authors.forename: Xin
authors.initials: X
authors.lastname: Li
authors.forename: Li-hua
authors.initials: LH
authors.lastname: Sun
authors.forename: Jian-cui
authors.initials: JC
authors.lastname: Qi
authors.forename: Yu-ying
authors.initials: YY
authors.lastname: Mao
authors.forename: Zhi-dan
authors.initials: ZD
authors.lastname: Sun
authors.forename: Zhi-min
authors.initials: ZM
authors.lastname: Du
mesh_terms: D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D006352:Heart Ventricles / Q000187:drug effects / Q000378:metabolism; D007501:Iron / Q000378:metabolism; D019190:Iron Overload / Q000188:drug therapy* / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013311:Streptozocin; D014700:Verapamil / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000889:Anti-Arrhythmia Agents; D001786:Blood Glucose; D002121:Calcium Channel Blockers; D013311:Streptozocin; D014700:Verapamil; D007501:Iron
references.citation: J Mol Med (Berl). 2006 May;84(5):349-64
references.pmid: 16604332
references.citation: Circ Res. 1999 Jun 11;84(11):1302-9
references.pmid: 10364568
references.citation: BMC Med Genomics. 2009 Jan 08;2:2
references.pmid: 19133145
references.citation: Eur J Haematol. 2011 Feb;86(2):156-66
references.pmid: 21059103
references.citation: Cell Physiol Biochem. 2010;25(6):587-94
references.pmid: 20511703
references.citation: Int J Hematol. 2008 Jul;88(1):7-15
references.pmid: 18594779
references.citation: Toxicol Appl Pharmacol. 2008 Jul 15;230(2):167-74
references.pmid: 18420243
references.citation: Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1236-43
references.pmid: 20354157
references.citation: Atherosclerosis. 2012 Jun;222(2):512-8
references.pmid: 22521900
references.citation: Free Radic Res. 2006 Mar;40(3):263-72
references.pmid: 16484042
references.citation: Cell Signal. 2012 May;24(5):981-90
references.pmid: 22286106
references.citation: Circulation. 2003 May 27;107(20):2601-6
references.pmid: 12732602
references.citation: Am J Physiol Renal Physiol. 2008 Oct;295(4):F1213-21
references.pmid: 18653481
references.citation: Eur J Haematol. 2012 Jun;88(6):476-7
references.pmid: 22420502
references.citation: Cell Physiol Biochem. 2011;27(1):23-30
references.pmid: 21325818
references.citation: Eur J Haematol. 2012 Jun;88(6):535-48
references.pmid: 22404220
references.citation: J Clin Invest. 2011 Apr;121(4):1386-96
references.pmid: 21364282
references.citation: Ophthalmic Res. 1998;30(2):107-12
references.pmid: 9523289
references.citation: Blood. 2012 Nov 1;120(18):3829-36
references.pmid: 22990014
references.citation: Biochim Biophys Acta. 2005 Apr 15;1740(1):79-84
references.pmid: 15878745
references.citation: Nat Med. 2003 Sep;9(9):1187-94
references.pmid: 12937413
references.citation: Toxicol Lett. 2004 Aug 30;152(1):19-25
references.pmid: 15294343
references.citation: Cell Physiol Biochem. 2010;26(3):421-30
references.pmid: 20798527
references.citation: Am J Hematol. 2005 Mar;78(3):225-31
references.pmid: 15726599
references.citation: Talanta. 2010 Aug 15;82(3):1052-6
references.pmid: 20678667
references.citation: Am J Physiol Endocrinol Metab. 2012 Jan 1;302(1):E77-86
references.pmid: 21917632
references.citation: Toxicol Appl Pharmacol. 2005 Jan 15;202(2):199-211
references.pmid: 15629195
references.citation: Diabetes. 2011 Jan;60(1):80-7
references.pmid: 20876715